MyBioSource.com
Empagliflozin
MBS843222
Info:Supplier Page View Product Specs View Product
Inflammation plays a crucial role in development and progression of cardiovascular damage in diabetes. We used LPS to induce inflammation in HL-1 cardiomyocytes. Empagliflozin pre-treatment inhibited LPS-induced TNFa release in the supernatant, as measured by ELISA.
Cell culture
Cardiomyocytes
N/A
Empagliflozin at 1 microM dose inhibited LPS-induced TNFa release from cardiomyocytes.
Worked as expected
Empagliflozin possesses potential cardioprotective effects.